Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Benefits of Actiphage

The ability to detect viable mycobacteria in the blood at an early stage of infection offers greater sensitivity in diagnosis, improved identification of carriers and more effective disease control.

Loading...

About Actiphage

Actiphage is unique as it is able to detect and identify live mycobacteria at a very early stage of infection,...

Rapid detection of mycobacterial disease

Actiphage provides a highly specific and sensitive assay for the cost-effective detection of mycobacterial disease in blood and milk.

Actiphage increases the speed and effectiveness of testing..

Faster testing time
Actiphage only requires one visit to collect blood samples and analysis takes 6-8 hours to produce a result.

No ‘cool off’ period
There is no time limit between tests, enabling a continuous programme of testing to be carried out where infection has been detected or is suspected.

Highly sensitive
The test only works on viable mycobacteria. Actiphage is more sensitive than any other test currently available, able to detect fewer than 10 live mycobacteria in a 2ml blood sample.

Highly specific
The technology has in-built high-level specificity controls and is able to identify any species of mycobacteria that is susceptible to the bacteriophage, including MAP (Johne’s disease) and M.bovis (bovine TB).

High accuracy
Actiphage can reproducibly distinguish between live and dead mycobacteria, meaning that a positive result will only be delivered if there are live mycobacteria in the sample.

As a tool for differentiating vaccinated from infected hosts
Uniquely, Actiphage directly detects live mycobacteria so will always produce a negative result when used on vaccinated subjects even if they might have a positive skin test result. This opens up the possibility of, for example, the roll-out of vaccination programmes.

Contact us to find out more

Towards eradicating tuberculosis

Actiphage has potential as a non-invasive screening tool for high-risk populations. It is able to detect mycobacteria in the blood, evidence of disease progression.

This is a vital first step towards eradication of devastating mycobacterial disease.

Related content

Loading...
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been revealed by the TAG pipeline report
TAG pipeline report on TB feat

Detecting subclinical TB – Actiphage only blood test for mycobacteria highlighted in TAG pipeline report

November 22, 2022
Actiphage is the only test in development for subclinical tuberculosis that directly detects mycobacteria in the blood, it has been...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
ECCMID conference

23-26 April 2022

Novel TB diagnostics paper to be presented at ECCMID 2022

April 4, 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session at ECCMID 2022
ECCMID conference

23-26 April 2022

Novel TB diagnostics paper to be presented at ECCMID 2022

April 4, 2022
Jee-Whang Kim of Leicester Tuberculosis Research Group (LTBRG) is to present a paper in the ‘hot topics in tuberculosis’ session...

From Farm to Fork, the power of phage

February 24, 2022
Phage diagnostics have potential for cost-effective detection of bacterial infections across medical, food, and agricultural industries says new review.

From Farm to Fork, the power of phage

February 24, 2022
Phage diagnostics have potential for cost-effective detection of bacterial infections across medical, food, and agricultural industries says new review.
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More